Reduced BNT162b2 mRNA vaccine response in SARS-CoV-2-naive nursing home residents
Naive human B cells can neutralize SARS-CoV-2 through recognition of its receptor binding domain
Engineered receptor binding domain immunogens elicit pan-coronavirus neutralizing antibodies
Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
Multiple circulating SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
T cell-tropic HIV efficiently infects alveolar macrophages through contact with infected CD4+T cells.
The persistence of interleukin-6 is regulated by a blood buffer system derived from dendritic cells
Enhancing durability of CIS43 monoclonal antibody by Fc mutation or AAV delivery for malaria prevention
Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production
COVID-19 neutralizing antibodies predict disease severity and survival
SARS-CoV-2-specific ELISA development
Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 Spike protein for neutralization assays
Spontaneous Glycan Reattachment Following N-Glycanase Treatment of Influenza and HIV Vaccine Antigens.
Delivering genes across the blood-brain barrier: LY6A, a novel cellular receptor for AAV-PHP.B capsids.
AAV-Mediated Expression of Broadly Neutralizing and Vaccine-like Antibodies Targeting the HIV-1 Envelope V2 Region.
Vectored delivery of anti-SIV envelope targeting mAb via AAV8 protects rhesus macaques from repeated limiting dose intrarectal swarm SIVsmE660 challenge.
Adeno-associated virus gene delivery of broadly neutralizing antibodies as prevention and therapy against HIV-1.
Antibody gene transfer with adeno-associated viral vectors as a method for HIV prevention.
Multilineage transduction of resident lung cells in vivo by AAV2/8 for alpha1-antitrypsin gene therapy.
Insulin-like growth factor 2 modulates murine hematopoietic stem cell maintenance through upregulation of p57.
Improvements and Limitations of Humanized Mouse Models for HIV Research.
Engineering humoral immunity as prophylaxis or therapy.
Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection.
Vectored antibody gene delivery for the prevention or treatment of HIV infection.
Broadly neutralizing antibodies abrogate established hepatitis C virus infection.
Vectored antibody gene delivery protects against Plasmodium falciparum sporozoite challenge in mice.
Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission.
Broad protection against influenza infection by vectored immunoprophylaxis in mice.
Antibody gene transfer for HIV immunoprophylaxis.
Antibody based protection against HIV infection by Vectored Immunoprophylaxis.Faculty of 1000 Evaluation
Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy.Faculty of 1000 Evaluation
Dimeric 2G12 as a potent protection against HIV-1.
Lentiviral vector delivery of human interleukin-7 (hIL-7) to human immune system (HIS) mice expands T lymphocyte populations.
MicroRNAs enriched in hematopoietic stem cells differentially regulate long-term hematopoietic output.
Mitotic spindle destabilization and genomic instability in Shwachman-Diamond syndrome.
Endothelial Protein C receptor (CD201) explicitly identifies hematopoietic stem cells in murine bone marrow.
Nitric oxide is a regulator of hematopoietic stem cell activity.
Viscoelastic properties of demineralized human dentin measured in water with atomic force microscope (AFM)-based indentation.